Literature DB >> 7591963

Cytotoxic activity of CD4+ T cells against autologous tumor cells.

Y Konomi1, T Sekine, T Takayama, M Fuji, T Tanaka.   

Abstract

The 51Cr-release assay is mostly applied to detecting the cytotoxic activity of CD8+ T cells, and little is known about the activity of CD4+ T cells. Therefore, the correlation between the cytotoxic activity of CD4+ or CD8+ T cells and the incubation period with autologous tumor cells was analyzed by two methods. The incubation periods were 4 and 20 h (4 h and 20 h assay) for the 51Cr-release assay. Eight pairs of tumor cells and T cells were assayed. T cells were fractionated into CD4+ and CD8+ T cells by using magnetic beads and panning methods, and those cells were activated by culture with recombinant interleukin-2 and immobilized anti-CD3 monoclonal antibody. In 6 out of 8 cases, no cytotoxic activity of CD4+ T cells was detected by the 4 h assay, whereas cytotoxic activity was detected in all cases in the 20 h assay. The cytotoxic activities in 20 h assay of CD4+ T cells were increased 67-fold in comparison with the activities in 4 h assay (range: 5-197). In the case of CD8+ T cells, cytotoxic activities were detected in 6 out of 8 cases in the 4 h assay. The lytic unit ratio of CD4+ and CD8+ T cells was calculated as 1.5 in the 20 h assay (range: 0.2- > 7.2) versus 0.4 in the 4 h assay (range: < 0.1-1.3). Cytotoxic activities in colorimetric assay using Crystal Violet with a 24 h incubation were similar to those in the 20 h 51Cr-release assay in all eight cases. These results indicate that CD4+ T cells have cytotoxic activity as strong as that of CD8+ T cells towards autologous tumor cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591963      PMCID: PMC5920933          DOI: 10.1111/j.1349-7006.1995.tb03096.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  33 in total

1.  Cytolytic and cytostatic activity on tumor cells of circulating human monocytes.

Authors:  A Mantovani; T R Jerrells; J H Dean; R B Herberman
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

2.  Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks.

Authors:  S Morecki; S L Topalian; W W Myers; D Okrongly; T B Okarma; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1990-10

3.  The use of [35S]methionine as a target cell label in long term cytotoxic assays.

Authors:  A Katz; M Feldman; L Eisenbach
Journal:  J Immunol Methods       Date:  1992-05-18       Impact factor: 2.303

4.  Rapid separation of CD4+ and CD19+ lymphocyte populations from human peripheral blood by a magnetic activated cell sorter (MACS).

Authors:  J W Semple; D Allen; W Chang; P Castaldi; J Freedman
Journal:  Cytometry       Date:  1993-11

5.  Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions.

Authors:  A Uchida; M Micksche
Journal:  Int J Cancer       Date:  1983-07-15       Impact factor: 7.396

6.  Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes.

Authors:  E K Main; L A Lampson; M K Hart; J Kornbluth; D B Wilson
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

7.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

8.  Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.

Authors:  A Mittelman; S Savona; E Gafney; K O Penichet; B Y Lin; D Levitt; T Ahmed; Z A Arlin; P Baskind; D Needleman
Journal:  J Biol Response Mod       Date:  1989-10

9.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection.

Authors:  A S Rosenberg; T Mizuochi; S O Sharrow; A Singer
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.